Publicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (31)

2024

  1. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

    Archivos de Bronconeumologia

  2. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

  3. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

    Lung Cancer, Vol. 190

2023

  1. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  2. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)

    Scientific Reports

  3. Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2679-2691), 10.1007/s12094-023-03216-3)

    Clinical and Translational Oncology

  4. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2679-2691

2022

  1. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192

  2. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry

    PLoS ONE, Vol. 16, Núm. 6 June

  2. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

  3. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

  2. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

    BMC Psychology, Vol. 8, Núm. 1

  3. Lung cancer symptoms at diagnosis: Results of a nationwide registry study

    ESMO Open, Vol. 5, Núm. 6

  4. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

    Lung Cancer, Vol. 147, pp. 83-90

  5. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation

    Cancer Epidemiology, Vol. 67

2019

  1. Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)

    Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475

  2. Lung cancer in Spanish women: The WORLD07 project

    European Journal of Cancer Care, Vol. 28, Núm. 1

  3. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 3-17